• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical pharmacokinetics of hydrallazine.

作者信息

Talseth T

出版信息

Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.

DOI:10.2165/00003088-197702050-00001
PMID:913002
Abstract
摘要

相似文献

1
Clinical pharmacokinetics of hydrallazine.
Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.
2
Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.一名快速乙酰化酶表型患者出现肼屈嗪诱导的类红斑狼疮综合征。
Br Med J. 1980 Jul 26;281(6235):273-4. doi: 10.1136/bmj.281.6235.273-a.
3
Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。
Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.
4
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.肼屈嗪诱发的类狼疮综合征患者的乙酰化酶表型
Acta Med Scand. 1976;200(5):367-71. doi: 10.1111/j.0954-6820.1976.tb08248.x.
5
Pharmacokinetics of hydralazine and the first pass effect.
Bol Asoc Med P R. 1983 Jun;75(6):276-9.
6
Hydralazine urinary metabolites in systemic lupus erythematosus.
Arthritis Rheum. 1973 Mar-Apr;16(2):217-20. doi: 10.1002/art.1780160212.
7
Prospective study of immunologic effects of hydralazine in hypertensive patients.肼屈嗪对高血压患者免疫效应的前瞻性研究。
Clin Pharmacol Ther. 1981 Apr;29(4):447-56. doi: 10.1038/clpt.1981.62.
8
Hydrallazine in hypertension: is there a safe dose?肼屈嗪治疗高血压：是否存在安全剂量？
Br Med J. 1980 Aug 2;281(6236):353-4. doi: 10.1136/bmj.281.6236.353.
9
Anaemia in the hydrallazine-induced Lupus syndrome.
Scott Med J. 1983 Apr;28(2):181-2. doi: 10.1177/003693308302800219.
10
Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
Clin Pharmacol Ther. 1989 Aug;46(2):177-81. doi: 10.1038/clpt.1989.123.

引用本文的文献

1
Recent progress in DNA methyltransferase inhibitors as anticancer agents.DNA甲基转移酶抑制剂作为抗癌药物的最新进展。
Front Pharmacol. 2022 Dec 16;13:1072651. doi: 10.3389/fphar.2022.1072651. eCollection 2022.
2
Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.乙酰转移酶 2 基因型对妊娠期肼屈嗪药代动力学的影响。
J Clin Pharmacol. 2019 Dec;59(12):1678-1689. doi: 10.1002/jcph.1477. Epub 2019 Jun 30.
3
Pharmacologic treatment of chronic pediatric hypertension.儿童慢性高血压的药物治疗

本文引用的文献

1
[A new group of hypotensive substances with a special mechanism of action].
Experientia. 1950 Jan 15;6(1):19-21. doi: 10.1007/BF02154049.
2
Renal hyperemia induced in man by a new phthalazine derivative.一种新型酞嗪衍生物在人体中诱发的肾充血。
Proc Soc Exp Biol Med. 1950 Jan;73(1):102. doi: 10.3181/00379727-73-17591.
3
Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method.采用静脉滴注技术结合化学方法对异烟肼人体代谢模式进行的研究。
Paediatr Drugs. 2005;7(1):27-40. doi: 10.2165/00148581-200507010-00003.
4
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448.
5
Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.甲状腺功能亢进对甲巯咪唑、普萘洛尔、美托洛尔和阿替洛尔药代动力学的影响。
Eur J Clin Pharmacol. 1982;21(5):379-84. doi: 10.1007/BF00542322.
6
Dosage adjustment in renal insufficiency.肾功能不全时的剂量调整。
Br J Clin Pharmacol. 1982 Feb;13(2):145-53. doi: 10.1111/j.1365-2125.1982.tb01349.x.
7
Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。
Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.
8
Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment.
Eur J Clin Pharmacol. 1984;27(2):159-63. doi: 10.1007/BF00544039.
9
Influence of food intake on presystemic clearance of drugs.食物摄入对药物首过清除率的影响。
Clin Pharmacokinet. 1983 Jul-Aug;8(4):286-96. doi: 10.2165/00003088-198308040-00002.
10
Vasodilator therapy in chronic congestive heart failure.慢性充血性心力衰竭的血管扩张剂治疗
Drugs. 1983 Aug;26(2):148-73. doi: 10.2165/00003495-198326020-00003.
Am Rev Respir Dis. 1960 Jan;81:1-8. doi: 10.1164/arrd.1960.81.1.1.
4
Cardiovascular and renal responses to the combination of hexamethonium and 1-hydrazinophthalazine (apresoline) in hypertensive subjects.高血压患者对六甲铵与1-肼基酞嗪（阿普利素灵）联合用药的心血管及肾脏反应
J Clin Invest. 1955 Jun;34(6):867-74. doi: 10.1172/JCI103142.
5
FACTORS AFFECTING ACETYLATION IN-VIVO OF PARA-AMINOBENZOIC ACID BY HUMAN SUBJECTS.影响人体对对氨基苯甲酸体内乙酰化作用的因素
Clin Sci. 1964 Aug;27:133-41.
6
HUMAN ACETYLATION POLYMORPHISM.人类乙酰化多态性
J Lab Clin Med. 1964 Mar;63:394-403.
7
A study of the mechanism of the hemodynamic effects of hydralazine in man.肼屈嗪对人体血流动力学影响机制的研究。
Acta Pharmacol Toxicol (Copenh). 1963;20(Suppl 1):1-53.
8
Site of action of hydralazine and dihydralazine in man.
Acta Pharmacol Toxicol (Copenh). 1959;16:113-28.
9
Physiological disposition of hydralazine (1-hydrazinophthalazine) and a method for its determination in biological fluids.
Arch Int Pharmacodyn Ther. 1961 Jun 1;132:1-15.
10
Pharmacological properties of hydrallazine, dihydrallazine and some related compounds.肼屈嗪、二氢肼屈嗪及一些相关化合物的药理特性。
J Pharm Pharmacol. 1957 Dec;9(12):877-87; discussion 887-8. doi: 10.1111/j.2042-7158.1957.tb12349.x.